GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.  A separate report found ...

Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through ...

Fifty years of outstanding neuroscience research studies have revealed many secrets of how drugs of abuse affect and change ...

More than a dozen lawsuits filed in New York and New Jersey claim that weight-loss drugs like Wegovy and Ozempic caused ...

Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...

Discover how GLP-1 drugs are driving demand for new supplements. Insights from Vitafoods Europe 2025 reveal how the industry ...

Wellness influencer Janelle Rohner has seen the internet’s criticism after revealing she micro-dosed GLP-1 to lose weight.

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...

Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, with many patients quitting GLP-1 treatment within a year.

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...